ESP and EORTC new fellowship collaboration to focus on research programs

In recognition of the central role of pathologists in clinical trials in the era of precision medicine and especially in the field of medical oncology, the European Organisation for Research and Treatment of Cancer (EORTC) and the European Society of Pathology (ESP) today launched a joint ESP-EORTC pathology research fellowship program.

In clinical trials, histological tumor markers assessed by the participating pathologists frequently serve as eligibility criteria for inclusion, stratification factors for target cohort identification or as surrogate endpoint to expedite the trial in neo-adjuvant setting.

In the increasingly common biomarker driven studies most of the time it is the responsibility of the pathology laboratory to ensure all prerequisites for reliable molecular testing and reporting.

In EORTC studies the custodians of annotated human biological samples are pathologists. They ensure the maintenance of quality assured bio-banks for next generation clinical trials and for future research ultimately leading to precision medicine.

The EORTC-ESP fellow is a young pathologist, who will work closely with key opinion leaders in the EORTC-ESP network and will participate in clinical research programs leading toward biomarker discovery and validation.

About ESP

The European Society of Pathology (ESP) is a leading force in European pathology.

As a learned society, the ESP has its primary aim in promoting high quality diagnostic practice, applied and translational research and under- and postgraduate education in the field of human pathology. This is achieved through its congresses, its journal Virchows Archiv, its Giordano Fellowship programs, its European School of Pathology, which organises a variety of postgraduate courses and its quality assurance projects in diagnostic molecular pathology.

The ESP interacts with national pathology societies in Europe and has developed close collaborations with European organizations and Associations sharing the same vision.

The ESP headquarters in Brussels serve as hub for European Pathology organisations.


The European Organisation for the Research and Treatment of Cancer (EORTC) brings together European cancer clinical research experts from all disciplines for trans-national collaboration.

Both multinational and multidisciplinary, the EORTC Network comprises more than 4,500 collaborators from all disciplines involved in cancer treatment and research in more than 600 hospitals in over 30 countries.

Through translational and clinical research, the EORTC offers an integrated approach to drug development, drug evaluation programs and medical practices.

EORTC Headquarters, a unique pan European clinical research infrastructure, is based in Brussels, Belgium, from where its various activities are coordinated and run.

Back to news list

Related News

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023